Kai Zhang1, Haiping Wang1, Mei Xu1, Jacqueline A Frank1, Jia Luo2. 1. Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, 132 Health Sciences Research Building, 1095 Veterans Drive, Lexington, KY, 40536, USA. 2. Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, 132 Health Sciences Research Building, 1095 Veterans Drive, Lexington, KY, 40536, USA. jialuo888@uky.edu.
Abstract
BACKGROUND: Neuroinflammation and microglial activation have been implicated in both alcohol use disorders (AUD) and fetal alcohol spectrum disorders (FASD). Chemokine monocyte chemoattractant protein 1 (MCP-1) and its receptor C-C chemokine receptor type 2 (CCR2) are critical mediators of neuroinflammation and microglial activation. FASD is the leading cause of mental retardation, and one of the most devastating outcomes of FASD is the loss of neurons in the central nervous system (CNS). The underlying molecular mechanisms, however, remain unclear. We hypothesize that MCP-1/CCR2 signaling mediates ethanol-induced neuroinflammation and microglial activation, which exacerbates neurodegeneration in the developing brain. METHODS: C57BL/6 mice and mice deficient of MCP-1 (MCP-1-/-) and CCR2 (CCR2-/-) were exposed to ethanol on postnatal day 4 (PD4). Neuroinflammation, and microglial activation, and neurodegeneration in the brain were evaluated by immunohistochemistry and immunoblotting. A neuronal and microglial co-culture system was used to evaluate the role of microglia and MCP-1/CCR2 signaling in ethanol-induced neurodegeneration. Specific inhibitors were employed to delineate the involved signaling pathways. RESULTS: Ethanol-induced microglial activation, neuroinflammation, and a drastic increase in the mRNA and protein levels of MCP-1. Treatment of Bindarit (MCP-1 synthesis inhibitor) and RS504393 (CCR2 antagonist) significantly reduced ethanol-induced microglia activation/neuroinflammation, and neuroapoptosis in the developing brain. MCP-1-/- and CCR2-/- mice were more resistant to ethanol-induced neuroapoptosis. Moreover, ethanol plus MCP-1 caused more neuronal death in a neuron/microglia co-culture system than neuronal culture alone, and Bindarit and RS504393 attenuated ethanol-induced neuronal death in the co-culture system. Ethanol activated TLR4 and GSK3β, two key mediators of microglial activation in the brain and cultured microglial cells (SIM-A9). Blocking MCP-1/CCR2 signaling attenuated ethanol-induced activation of TLR4 and GSK3β. CONCLUSION: MCP-1/CCR2 signaling played an important role in ethanol-induced microglial activation/neuroinflammation and neurodegeneration in the developing brain. The effects may be mediated by the interaction among MCP-1/CCR2 signaling, TLR4, and GSK3β.
BACKGROUND:Neuroinflammation and microglial activation have been implicated in both alcohol use disorders (AUD) and fetal alcohol spectrum disorders (FASD). Chemokine monocyte chemoattractant protein 1 (MCP-1) and its receptor C-C chemokine receptor type 2 (CCR2) are critical mediators of neuroinflammation and microglial activation. FASD is the leading cause of mental retardation, and one of the most devastating outcomes of FASD is the loss of neurons in the central nervous system (CNS). The underlying molecular mechanisms, however, remain unclear. We hypothesize that MCP-1/CCR2 signaling mediates ethanol-induced neuroinflammation and microglial activation, which exacerbates neurodegeneration in the developing brain. METHODS: C57BL/6 mice and mice deficient of MCP-1 (MCP-1-/-) and CCR2 (CCR2-/-) were exposed to ethanol on postnatal day 4 (PD4). Neuroinflammation, and microglial activation, and neurodegeneration in the brain were evaluated by immunohistochemistry and immunoblotting. A neuronal and microglial co-culture system was used to evaluate the role of microglia and MCP-1/CCR2 signaling in ethanol-induced neurodegeneration. Specific inhibitors were employed to delineate the involved signaling pathways. RESULTS:Ethanol-induced microglial activation, neuroinflammation, and a drastic increase in the mRNA and protein levels of MCP-1. Treatment of Bindarit (MCP-1 synthesis inhibitor) and RS504393 (CCR2 antagonist) significantly reduced ethanol-induced microglia activation/neuroinflammation, and neuroapoptosis in the developing brain. MCP-1-/- and CCR2-/- mice were more resistant to ethanol-induced neuroapoptosis. Moreover, ethanol plus MCP-1 caused more neuronal death in a neuron/microglia co-culture system than neuronal culture alone, and Bindarit and RS504393 attenuated ethanol-induced neuronal death in the co-culture system. Ethanol activated TLR4 and GSK3β, two key mediators of microglial activation in the brain and cultured microglial cells (SIM-A9). Blocking MCP-1/CCR2 signaling attenuated ethanol-induced activation of TLR4 and GSK3β. CONCLUSION:MCP-1/CCR2 signaling played an important role in ethanol-induced microglial activation/neuroinflammation and neurodegeneration in the developing brain. The effects may be mediated by the interaction among MCP-1/CCR2 signaling, TLR4, and GSK3β.
Authors: Philip A May; Amy Baete; Jaymi Russo; Amy J Elliott; Jason Blankenship; Wendy O Kalberg; David Buckley; Marita Brooks; Julie Hasken; Omar Abdul-Rahman; Margaret P Adam; Luther K Robinson; Melanie Manning; H Eugene Hoyme Journal: Pediatrics Date: 2014-11 Impact factor: 7.124
Authors: Ismini E Papageorgiou; Andrea Lewen; Lukas V Galow; Tiziana Cesetti; Jörg Scheffel; Tommy Regen; Uwe-Karsten Hanisch; Oliver Kann Journal: Proc Natl Acad Sci U S A Date: 2015-12-22 Impact factor: 11.205
Authors: Deren Huang; Jerome Wujek; Graham Kidd; Toby T He; Astrid Cardona; Margaret E Sasse; Erica J Stein; Jacqueline Kish; Marie Tani; Israel F Charo; Amanda E Proudfoot; Barrett J Rollins; Tracy Handel; Richard M Ransohoff Journal: FASEB J Date: 2005-05 Impact factor: 5.191
Authors: Jean A King; Benjamin C Nephew; Asmita Choudhury; Guillaume L Poirier; Arlene Lim; Pranoti Mandrekar Journal: Alcohol Date: 2019-08-06 Impact factor: 2.405
Authors: G N Zyuz'kov; V V Zhdanov; L A Miroshnichenko; T Yu Polyakova; E V Simanina; M G Danilets; M Yu Minakova; A A Churin; V I Agafonov Journal: Bull Exp Biol Med Date: 2022-05-02 Impact factor: 0.804
Authors: G N Zyuz'kov; L A Miroshnichenko; T Yu Polyakova; V V Zhdanov; E V Simanina; L A Stavrova; A A Churin; T I Fomina Journal: Bull Exp Biol Med Date: 2021-10-28 Impact factor: 0.804
Authors: Cynthia J M Kane; James C Douglas; Tonya Rafferty; Jennifer W Johnson; Victoria M Niedzwiedz-Massey; Kevin D Phelan; Ania Katarzyna Majewska; Paul D Drew Journal: J Neurosci Res Date: 2021-02-02 Impact factor: 4.433
Authors: Victoria M Niedzwiedz-Massey; James C Douglas; Tonya Rafferty; Patricia A Wight; Cynthia J M Kane; Paul D Drew Journal: Neurotoxicol Teratol Date: 2021-07-10 Impact factor: 4.071